Rana R McKay1, Xun Lin2, Julia J Perkins2, Daniel Y C Heng3, Ronit Simantov2, Toni K Choueiri4. 1. Dana-Farber Cancer Institute, Boston, MA, USA. 2. Pfizer Oncology, New York, NY, USA. 3. Tom Baker Cancer Center, Calgary, Alberta, Canada. 4. Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@DFCI.harvard.edu.
Abstract
BACKGROUND: Bone metastases (BMs) are frequently present in patients with metastatic renal cell carcinoma (mRCC) and cause significant morbidity. OBJECTIVE: The purpose of this analysis was to assess the impact of BMs and bisphosphonate therapy (BT) on outcomes in mRCC. DESIGN, SETTING, AND PARTICIPANTS: We conducted a pooled analysis of patients with mRCC treated from 2003 to 2011 in phase 2 and 3 trials. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statistical analyses were performed using Cox regression and the Kaplan-Meier method. RESULTS AND LIMITATIONS: We identified 2749 patients treated with sunitinib (n=1059), sorafenib (n=355), axitinib (n=359), temsirolimus (n=208), temsirolimus plus interferon-α (IFN-α) (n=208), or IFN-α (n=560), with 28% (n=781) having BMs. A total of 285 patients (10.4%) received BT. The presence of BMs in patients was associated with shorter overall survival (OS) when compared with patients without BMs (13.2 vs 20.2 mo, respectively; p<0.0001) and shorter progression-free survival (PFS) (5.1 vs 6.7 mo, respectively; p<0.0008). When stratified by risk groups, the presence of BMs was associated with shorter OS in all risk groups. The use of BT in patients with BMs was not associated with improved OS compared with patients who did not receive BT (13.3 vs 13.1 mo, respectively; p=0.3801) or improved PFS (5.1 vs 4.9 mo, respectively; p=0.1785). Bisphosphonate users with BMs did not have a decreased rate of skeletal-related events (SREs) compared with nonusers (8.6% vs 5.8%, respectively; p=0.191). In addition, BT was associated with increased rates of hypocalcemia, renal insufficiency, and osteonecrosis of the jaw (p<0.0001). Data were analyzed retrospectively. CONCLUSIONS: We confirm that the presence of BMs is associated with shorter survival in mRCC. BT did not affect survival or SRE prevention and was associated with increased toxicity. PATIENT SUMMARY: In this analysis, we demonstrate that bone metastases are associated with shorter survival in patients with metastatic renal cell carcinoma. In addition, we call into question the utility of bisphosphonate therapy in this population.
BACKGROUND:Bone metastases (BMs) are frequently present in patients with metastatic renal cell carcinoma (mRCC) and cause significant morbidity. OBJECTIVE: The purpose of this analysis was to assess the impact of BMs and bisphosphonate therapy (BT) on outcomes in mRCC. DESIGN, SETTING, AND PARTICIPANTS: We conducted a pooled analysis of patients with mRCC treated from 2003 to 2011 in phase 2 and 3 trials. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statistical analyses were performed using Cox regression and the Kaplan-Meier method. RESULTS AND LIMITATIONS: We identified 2749 patients treated with sunitinib (n=1059), sorafenib (n=355), axitinib (n=359), temsirolimus (n=208), temsirolimus plus interferon-α (IFN-α) (n=208), or IFN-α (n=560), with 28% (n=781) having BMs. A total of 285 patients (10.4%) received BT. The presence of BMs in patients was associated with shorter overall survival (OS) when compared with patients without BMs (13.2 vs 20.2 mo, respectively; p<0.0001) and shorter progression-free survival (PFS) (5.1 vs 6.7 mo, respectively; p<0.0008). When stratified by risk groups, the presence of BMs was associated with shorter OS in all risk groups. The use of BT in patients with BMs was not associated with improved OS compared with patients who did not receive BT (13.3 vs 13.1 mo, respectively; p=0.3801) or improved PFS (5.1 vs 4.9 mo, respectively; p=0.1785). Bisphosphonate users with BMs did not have a decreased rate of skeletal-related events (SREs) compared with nonusers (8.6% vs 5.8%, respectively; p=0.191). In addition, BT was associated with increased rates of hypocalcemia, renal insufficiency, and osteonecrosis of the jaw (p<0.0001). Data were analyzed retrospectively. CONCLUSIONS: We confirm that the presence of BMs is associated with shorter survival in mRCC. BT did not affect survival or SRE prevention and was associated with increased toxicity. PATIENT SUMMARY: In this analysis, we demonstrate that bone metastases are associated with shorter survival in patients with metastatic renal cell carcinoma. In addition, we call into question the utility of bisphosphonate therapy in this population.
Authors: Daniel Keizman; Maya Ish-Shalom; Roberto Pili; Hans Hammers; Mario A Eisenberger; Victoria Sinibaldi; Ben Boursi; Natalie Maimon; Maya Gottfried; Henry Hayat; Avivit Peer; Svetlana Kovel; Avishay Sella; Raanan Berger; Michael A Carducci Journal: Eur J Cancer Date: 2012-03-10 Impact factor: 9.162
Authors: Nalini Sathiakumar; Elizabeth Delzell; Michael A Morrisey; Carla Falkson; Mellissa Yong; Victoria Chia; Justin Blackburn; Tarun Arora; Ilene Brill; Meredith L Kilgore Journal: Breast Cancer Res Treat Date: 2011-08-13 Impact factor: 4.872
Authors: David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey Journal: Nat Rev Drug Discov Date: 2012-05 Impact factor: 84.694
Authors: N Sathiakumar; E Delzell; M A Morrisey; C Falkson; M Yong; V Chia; J Blackburn; T Arora; M L Kilgore Journal: Prostate Cancer Prostatic Dis Date: 2011-03-15 Impact factor: 5.554
Authors: M Bianchi; M Sun; C Jeldres; S F Shariat; Q-D Trinh; A Briganti; Z Tian; J Schmitges; M Graefen; P Perrotte; M Menon; F Montorsi; P I Karakiewicz Journal: Ann Oncol Date: 2011-09-02 Impact factor: 32.976
Authors: Rana R McKay; Nils Kroeger; Wanling Xie; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Mary J MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Sun-Young Rha; Sumanta K Pal; Frede Donskov; Srinivas K Tantravahi; Brian I Rini; Daniel Y C Heng; Toni K Choueiri Journal: Eur Urol Date: 2013-08-15 Impact factor: 20.096
Authors: F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey Journal: Ann Oncol Date: 2011-10-10 Impact factor: 32.976
Authors: B Beuselinck; P Wolter; A Karadimou; R Elaidi; H Dumez; A Rogiers; T Van Cann; L Willems; J-J Body; J Berkers; H Van Poppel; E Lerut; P Debruyne; R Paridaens; P Schöffski Journal: Br J Cancer Date: 2012-11-06 Impact factor: 7.640
Authors: Bernard Escudier; Thomas Powles; Robert J Motzer; Thomas Olencki; Osvaldo Arén Frontera; Stephane Oudard; Frederic Rolland; Piotr Tomczak; Daniel Castellano; Leonard J Appleman; Harry Drabkin; Daniel Vaena; Steven Milwee; Jillian Youkstetter; Julie C Lougheed; Sergio Bracarda; Toni K Choueiri Journal: J Clin Oncol Date: 2018-01-08 Impact factor: 44.544
Authors: Rana R McKay; Dominick Bossé; Kathryn P Gray; M Dror Michaelson; Katherine Krajewski; Heather A Jacene; Meghara Walsh; Joaquim Bellmunt; Mark Pomerantz; Lauren C Harshman; Toni K Choueiri Journal: Clin Cancer Res Date: 2018-05-30 Impact factor: 12.531
Authors: Nieves Martínez Chanzá; Wanling Xie; Mehmet Asim Bilen; Hannah Dzimitrowicz; Jarred Burkart; Daniel M Geynisman; Archana Balakrishnan; I Alex Bowman; Rohit Jain; Walter Stadler; Yousef Zakharia; Vivek Narayan; Benoit Beuselinck; Rana R McKay; Abhishek Tripathi; Russell Pachynski; Andrew W Hahn; JoAnn Hsu; Sumit A Shah; Elaine T Lam; Tracy L Rose; Anthony E Mega; Nicholas Vogelzang; Michael R Harrison; Amir Mortazavi; Elizabeth R Plimack; Ulka Vaishampayan; Hans Hammers; Saby George; Naomi Haas; Neeraj Agarwal; Sumanta K Pal; Sandy Srinivas; Benedito A Carneiro; Daniel Y C Heng; Dominick Bosse; Toni K Choueiri; Lauren C Harshman Journal: Lancet Oncol Date: 2019-02-28 Impact factor: 41.316
Authors: P Ivanyi; J Koenig; A Trummer; J F Busch; C Seidel; C W Reuter; A Ganser; V Grünwald Journal: World J Urol Date: 2015-11-19 Impact factor: 4.226